BACKGROUND: Standard glioblastoma therapy is long-lasting. Among second-line therapy, choices could be bevacizumab and nitrosoureas depending on National Agencies approval. There is no consensus on 3rd line therapy or clinical trials specifically designed for this setting. METHODS: We reviewed our institutional database on all consecutive patients who received 3rd line therapy for glioblastoma. RESULTS: Data on 168 out of 1337 (12.6%) glioblastoma patients who underwent 3rd line therapy treatment were collected. Third line treatments were bevacizumab or chemotherapy (nitrosourea, temozolomide or carboplatin plus etoposide). Median progression free survival was 2.9 months and median survival time was 6.6 months from the start of 3rd line therapy. Bevacizumab significantly improved progression-free survival (4.7 vs. 2.6 months, p = .020) and survival from 3rd line start (8.0 vs. 6.0 months, p = .014) in respect to chemotherapy. Toxicity of grade ≥ 3 occurred in 13.7% of patients. In multivariate analysis, survival in 3rd line treatment depends on MGMT methylation (p = .006) and treatment with Bevacizumab (p = .011). CONCLUSIONS: Third line therapy in selected glioblastoma patients may be feasible and well tolerated. Bevacizumab improved outcome in 3rd line in respect to chemotherapy.
BACKGROUND: Standard glioblastoma therapy is long-lasting. Among second-line therapy, choices could be bevacizumab and nitrosoureas depending on National Agencies approval. There is no consensus on 3rd line therapy or clinical trials specifically designed for this setting. METHODS: We reviewed our institutional database on all consecutive patients who received 3rd line therapy for glioblastoma. RESULTS: Data on 168 out of 1337 (12.6%) glioblastomapatients who underwent 3rd line therapy treatment were collected. Third line treatments were bevacizumab or chemotherapy (nitrosourea, temozolomide or carboplatin plus etoposide). Median progression free survival was 2.9 months and median survival time was 6.6 months from the start of 3rd line therapy. Bevacizumab significantly improved progression-free survival (4.7 vs. 2.6 months, p = .020) and survival from 3rd line start (8.0 vs. 6.0 months, p = .014) in respect to chemotherapy. Toxicity of grade ≥ 3 occurred in 13.7% of patients. In multivariate analysis, survival in 3rd line treatment depends on MGMT methylation (p = .006) and treatment with Bevacizumab (p = .011). CONCLUSIONS: Third line therapy in selected glioblastomapatients may be feasible and well tolerated. Bevacizumab improved outcome in 3rd line in respect to chemotherapy.
Authors: Alba A Brandes; Enrico Franceschi; Alexandro Paccapelo; Giovanni Tallini; Dario De Biase; Claudio Ghimenton; Daniela Danieli; Elena Zunarelli; Giovanni Lanza; Enrico Maria Silini; Carmelo Sturiale; Lorenzo Volpin; Franco Servadei; Andrea Talacchi; Antonio Fioravanti; Maria Pia Foschini; Stefania Bartolini; Annalisa Pession; Mario Ermani Journal: Oncologist Date: 2017-03-08
Authors: Patrick Y Wen; Susan M Chang; Martin J Van den Bent; Michael A Vogelbaum; David R Macdonald; Eudocia Q Lee Journal: J Clin Oncol Date: 2017-06-22 Impact factor: 44.544
Authors: Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Antje Wick; Christina Pascher; Wolfgang Wick; Tanja Jauch; Michael Weller; Ulrich Bogdahn; Peter Hau Journal: J Neurol Date: 2009-02-25 Impact factor: 4.849
Authors: Walter Taal; Joyce M W Segers-van Rijn; Johan M Kros; Irene van Heuvel; Carin C D van der Rijt; Jacoline E Bromberg; Peter A E Sillevis Smitt; Martin J van den Bent Journal: J Neurooncol Date: 2012-03-07 Impact factor: 4.130
Authors: A A Brandes; A Tosoni; G Cavallo; R Bertorelle; V Gioia; E Franceschi; M Biscuola; V Blatt; L Crinò; M Ermani Journal: Br J Cancer Date: 2006-10-03 Impact factor: 7.640